HIGHLIGHTS
- who: Anna Manzo from the Kantonsspital StGallen, Switzerland University of Turin, Italy have published the research work: Lurbinectedin in small cell lung cancer, in the Journal: (JOURNAL) of 15/06/2020
- future: Evaluation of lurbinectedin activity in patients with CNS metastases is needed.
SUMMARY
ORR was 91.7% for 12 patients with platinum-sensitive disease and 33.3% for nine patients with platinum-resistant disease. Lurbinectedin dose has been modified at 2 mg/m2 of BSA based on the finding that patients with the lowest BSA had an increased risk of . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.